

24 July 2020

ASX ANNOUNCEMENT

RESPONSE TO MARKET SPECULATION

Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) notes shareholder enquiries about the ASX Announcements advising of Changes of interests by substantial shareholders. Anteris confirms that it is not aware of any information that has not been announced to market which, if known by some in the market, could explain the reason for the sale of shares by the substantial shareholders.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company focused on delivering clinically superior solutions that create life-changing outcomes for patients. Its ADAPT[®] tissue platform, a next generation technology with zero DNA and zero glutaraldehyde, is the only bioscaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery. With these advantages, Anteris's best-in-class ADAPT[®] tissue combined with its valve design has the potential to solve the problems associated with current aortic valve replacement options which are durability and preventing valve degradation.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 401 018 828

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech

Anteris Technologies Ltd

Registered Office:

Suite 302, Level 3 Toowong Tower, 9 Sherwood Road, Toowong QLD 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299
E: info@anteristech.com W: anteristech.com

